Cargando…

A Nomogram Modeling (11)C-MET PET/CT and Clinical Features in Glioma Helps Predict IDH Mutation

Purpose: We developed a (11)C-Methionine positron emission tomography/computed tomography ((11)C-MET PET/CT)-based nomogram model that uses easy-accessible imaging and clinical features to achieve reliable non-invasive isocitrate dehydrogenase (IDH)-mutant prediction with strong clinical translation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Weiyan, Zhou, Zhirui, Wen, Jianbo, Xie, Fang, Zhu, Yuhua, Zhang, Zhengwei, Xiao, Jianfei, Chen, Yijing, Li, Ming, Guan, Yihui, Hua, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396495/ https://www.ncbi.nlm.nih.gov/pubmed/32850348 http://dx.doi.org/10.3389/fonc.2020.01200

Ejemplares similares

The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A (11)C-MET PET Study
por: Kudulaiti, Nijiati, et al.
Publicado: (2019)

Integrated CT Radiomics Features Could Enhance the Efficacy of (18)F-FET PET for Non-Invasive Isocitrate Dehydrogenase Genotype Prediction in Adult Untreated Gliomas: A Retrospective Cohort Study
por: Zhou, Weiyan, et al.
Publicado: (2021)

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
por: Liu, Feng-Min, et al.
Publicado: (2021)

Predicting IDH genotype in gliomas using FET PET radiomics
por: Lohmann, Philipp, et al.
Publicado: (2018)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
por: Wollring, Michael M., et al.
Publicado: (2022)

Prediction of Glioma Grade and IDH Status Using (18)F-FET PET/CT Dynamic and Multiparametric Texture Analysis
por: Hajri, Rami, et al.
Publicado: (2023)

Diagnostic value of PET/CT with (11)C-methionine (MET) and (18)F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification
por: Ogawa, Tomoya, et al.
Publicado: (2020)

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
por: Skoblar Vidmar, Marija, et al.
Publicado: (2022)

Successful Treatment for Adult Precursor B-Cell Lymphoblastic Lymphoma Involving Central Nervous System Monitored by (18)F-Fluorodeoxyglucose PET/CT Imaging
por: Shi, Xiang, et al.
Publicado: (2020)

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival
por: Korkolopoulou, P, et al.
Publicado: (2013)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Wang, Ke, et al.
Publicado: (2021)

Sex-specific radiomic features of L-[S-methyl-(11)C] methionine PET in patients with newly-diagnosed gliomas in relation to IDH1 predictability
por: Papp, Laszlo, et al.
Publicado: (2023)

Usefulness of FDG, MET and FLT-PET Studies for the Management of Human Gliomas
por: Miyake, Keisuke, et al.
Publicado: (2012)

A Head-to-Head Comparison of (18)F-Fluorocholine PET/CT and Conventional MRI as Predictors of Outcome in IDH Wild-Type High-Grade Gliomas
por: Garcia Vicente, Ana María, et al.
Publicado: (2022)

NI-13 Prediction of outcome at the time of discontinuing TMZ-adjuvant therapy in IDH-mutant lower grade glioma using (11)C-methinine PET
por: Beppu, Takaaki, et al.
Publicado: (2021)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

(18)F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors
por: Mittlmeier, Lena M., et al.
Publicado: (2021)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Characteristics of gliomas in patients with somatic IDH mosaicism
por: Bonnet, Charlotte, et al.
Publicado: (2016)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

PET/CT-based radiomics analysis may help to predict neoadjuvant chemotherapy outcomes in breast cancer
por: Yang, Liping, et al.
Publicado: (2022)

(11)C–acetate PET/CT: a potential alternative of transcranial biopsy for grading cerebral gliomas
por: Hatazawa, Jun
Publicado: (2018)

Increased TSPO PET signal after radiochemotherapy in IDH-wildtype glioma—indicator for treatment-induced immune activation?
por: Quach, Stefanie, et al.
Publicado: (2022)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma
por: van Dijken, Bart R. J., et al.
Publicado: (2022)

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival
por: Yao, Yu, et al.
Publicado: (2013)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
por: Flanagan, Simon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_uenr6dbi0808m9nk6ufqiuh6as